Phase 1/2 Trial Begins on ONCOS-102, Imfinzi Combination in Advanced Ovarian, Colorectal Cancers

Phase 1/2 Trial Begins on ONCOS-102, Imfinzi Combination in Advanced Ovarian, Colorectal Cancers
A new Phase 1/2 clinical trial has been launched testing a combination of investigational viral therapy ONCOS-102 and Imfinzi (durvalumab) in patients with advanced ovarian and colorectal cancers. The open-label trial (NCT02963831) has already enrolled and evaluated the first group of patients, and is continuing to recruit as many as 78 patients at multiple centers across the U.S. It is being led by researchers at Ludwig Cancer Research and the Cancer Research Institute (CRI) in collaboration with MedImmune, Imfinzi's maker, and Targovax, which is developing ONCOS-102. To be eligible, patients must have failed prior standard chemotherapy for either ovarian or colorectal cancer, and have failed to benefit or stopped responding to platinum-based chemotherapy, with no additional therapeutic options available. “Patients diagnosed with advanced ovarian and colorectal cancers that have progressed on standard therapies have very few treatment options available to them,” Vanessa Lucey, PhD, director of the CRI Venture Fund and Clinical Accelerator, said in a press release. “Under a unique partnership model, this study leverages the capabilities of two
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *